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Modulation of experimental mesangial proliferative nephritis by inter-
feron-y. The observation that interferon-y (IFN-y) inhibits cell prolifer-
ation and collagen synthesis of a variety of cell types in culture has
suggested that IFN-y may be useful in the treatment of fibroproliferative
diseases. We administered recombinant IFN-y subcutaneously (10 U/kg!
day for 3 days) to rats, beginning one day after the induction of mesangial
proliferative nephritis with anti-Thy 1 antibody. IFN-y reduced glomeru-
lar (primarily mesangial) cell proliferation by 44% at days 2 and 4
compared to vehicle injected control rats with anti-Thy I nephritis (that is,
proliferating cells that excluded the macrophage marker, ED-i, P <
0.001). Despite the inhibition of mesangial cell proliferation, IFN-y did
not reduce the overall extracellular matrix deposition (by silver stain) or
deposition of type IV collagen or laminin (by immunostaining) at 4 or 7
days, and glomerular type IV collagen and laminin mRNA levels were
increased (1.4 and 1.7-fold) at 4 days relative to controls. The inability of
IFN-y treatment to reduce mesangial matrix expansion may relate to the
fact that IFN-y treated rats had a twofold increase in glomerular
macrophages (that is, ED-i positive cells, P < 0.001 at 2 and 4 days) with
an increase in oxidant producing cells (day 2, P < 0.05) and a 1.6-fold
increase in glomerular TGF-p mRNA expression (4 days). This suggests
that the effect of IFN-y to inhibit mesangial cell proliferation in glomer-
ulonephritis may be offset by the ability of IFN-y to increase glomerular
macrophages and TGF-13 expression. These data also show that IFN-y can
partly dissociate the mesangial proliferative response from the extracellu-
lar matrix expansion in glomerulonephritis.
Mesangial cell proliferation can be documented in numerous
experimental and human glomerular diseases [1—6]. The mesang-
ial cell proliferation in these diseases is associated with a pheno-
typic change in which the mesangial cells express proteins char-
acteristic of vascular smooth muscle cells (that is, a-smooth
muscle actin) and fibroblasts (that is, type I interstitial collagen)
[2, 5—8]. This has suggested to us that the activated mesangial cells
in these lesions may be acquiring characteristics of "myofibro-
blasts" [9].
Although it is possible that some mesangial cell proliferation
and phenotypic changes are of benefit to the host in the normal
reparative response to glomerular injury, there is evidence that
excessive cell proliferation may have a pathogenic role in the
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development of glomerular sclerosis. First, mesangial cell prolif-
eration precedes and is tightly linked to the development of
extracellular matrix expansion and/or sclerosis in experimental
models of nephritis [2—4, 8, 101. Mesangial cell proliferation may
also persist in experimental [2, 4] and human [6] glomerular
diseases associated with advanced glomeruloscierosis. Finally,
measures that reduce cell proliferation in experimental disease
models, such as treatment with heparin [11], low protein diet [10],
or neutralizing antibody to platelet-derived growth factor (PDGF)
[12], also reduce the extracellular matrix expansion or sclerosis.
We were therefore interested in examining the effects of agents
that might inhibit mesangial cell proliferation in a model of
mesangial proliferative nephritis. Several substances have been
reported to inhibit mesangial cell proliferation in vitro, including
heparin, heparan sulfate proteoglycan, nitric oxide (endothelium
derived relaxing factor), atrial natriuretic factor, and interferon-y
(IFN-y) [13—17, and reviewed in 18]. Treatment with IFN-y is
especially appealing as this cytokine is not only anti-proliferative
for a variety of cell types [16—22], but also inhibits other proper-
ties observed in myofibroblasts, such as a-smooth muscle actin
expression (in smooth muscle cells and fibroblasts) [19, 23, 24] and
collagen production (in fibroblasts) [25—28]. Indeed, IFN-y inhib-
its cell proliferation, a-smooth muscle actin expression, and
collagen production in cultured hepatic lipocytes [23], a cell that
is remarkably analogous to the mesangial cell in the way it
responds in fibrosing hepatic diseases [29]. We now report the
effect of IFN-y treatment in a rat model of experimental mesang-
ial proliferative nephritis.
Methods
Experimental protocol
Mesangial proliferative nephritis was induced in 150 g male
Wistar rats (Simonsen Laboratories, Gilroy, CA, USA) by intra-
venous injection with antibody to the Thy 1 antigen on the
mesangial cell membrane (0.50 ml anti-Thy 1 plasma/100 g body
wt) as previously described [7]. Recombinant rat IFN-y (10 U/kg
in 0.2 ml normal saline, gift of Peter van der Meide, TNO Primate
Center, Rijswijk, The Netherlands) or normal saline alone was
then injected subcutaneously at 20, 44, and 68 hours after disease
induction. IFN-y or vehicle injected rats underwent kidney biop-
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sies at days 2 (N = 6 per group), 4 (N = 10 per group) and day 7
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(N = 4 per group). No rat was biopsied more than two times. At
days 4 and 7 glomeruli were isolated and RNA extracted for
Northern analysis. Serum (day 4) and urine (day 3 to 4) were also
collected for blood urea nitrogen and urine protein measure-
ments. Finally, normal rats were injected with similar doses of
IFN-y (N = 2) or vehicle (N = 4) and biopsied at days 4 and 7
using identical handling and housing procedures as that per-
formed on rats with anti-Thy 1 disease.
Immunostaining
Methyl Carnoy's fixed tissue was processed and 4 m sections
were stained with the periodic acid/Schiff reagent and counter-
stained with hematoxylin. Additional sections from each biopsy
were immunostained by an avidin/biotin indirect iicimunoperoxi-
dase method [7] with the following primary antibodies: 19A2
(Coulter, Hialeah, FL, USA), a murine monoclonal 1gM to the
proliferating cell nuclear antigen (PCNA; [30]); ED-i (Bioprod-
ucts for Science, Indianapolis, IN, USA), a murine monoclonal
IgG to monocyte-macrophages [31]; RP-3 (gift of F. Sendo,
Yamagata, Japan), a monoclonal 1gM to rat neutrophils [32];
OX-22 (Accurate Chemical Corporation, Westbury, NY, USA), a
monoclonal IgG to the high molecular weight form of the
common leukocyte antigen expressed on B-lymphocytes and some
T-lymphocytes; asm-i, a monoclonal IgG to the NH2-terminal
synthetic decapeptide of a-smooth muscle actin [33]; polyclonal
rabbit anti-rat laminin (Chemicon, Temecula, CA, USA); poly-
clonal guinea pig anti-rat type I collagen (gift of L. Iruela-Arispe;
[34]); and polyclonal rabbit anti-mouse type IV collagen (Collab-
orative Research, Bedford, MA, USA) [8]. Tissue was also double
immunostained for both proliferating cells (PCNA) and macro-
phages (with ED-i) by an indirect immunogold procedure as
described [1, 35]. Negative controls consisted of replacing the
primary antibody with either an irrelevant murine monoclonal or
rabbit polyclonal antibody.
Kidney tissue from the day 2 biopsies was also snap-frozen in
liquid nitrogen and 6 m sections stained for hydrogen peroxide
produced by activated neutrophils and monocytes. Hydrogen
peroxide-generating cells were identified by reaction of the hy-
drogen peroxide with diaminobenzidine in the presence of myelo-
peroxidase [36], the latter which is present in neutrophils and
monocytes.
Quantitation of proliferating (PCNA positive) and oxidant
positive cells and of the various leukocyte populations within
glomeruli was performed by enumerating the number of positively
stained cells in 20 or more sequentially examined glomerular cross
sections per biopsy in blinded manner as previously described [1,
7, 35]. Glomeruli were also graded semiquantitatively (scale 0 to
4+) for the degree of mesangial staining of types I and IV
collagen, laminin, and a-smooth muscle actin in blinded fashion
as previously described [81. For a-smooth muscle actin, scoring
was as follows: 0, no a actin present; 1+, up to 25% of glomerular
tuft positive; 2+, 25 to 50% of glomerular tuft positive; 3+, 50 to
75% positive; 4+, 75 to 100% of tuft positive. For the extracellular
matrix components, scoring was as follows: 0, absent mesangial
matrix staining (observed only with type I collagen); 1+, diffuse
and weak mesangial staining with i to 25% of glomerular tuft
showing local increased staining; 2+, 25 to 50% of glomerular tuft
with focal strong staining; 3+, 50 to 75% of glomerular tuft with
strong staining; 4+, > 75% of glomerular tuft with increased
staining. Scores primarily reflect change in distribution rather
than intensity of mesangial staining, and representative glomeruli
with different scores of collagen IV staining are shown in Figure
1. For each biopsy, a mean score was calculated and was then used
to generate a mean SD for each group.
Northern analysis
Glomeruli were isolated from three to four rats from each
group at days 4 and 7, pooled, and the total RNA extracted [7]
with RNAzo1 B (Cinna/Biotecx Laboratories, Friendswood,
Texas, USA) according to the manufacturer's instructions and
further purified by LiC1 precipitation as previously described [2].
For Northern analysis the RNA was denatured and 15 j.tg/lane
were electrophoresed through a 1% formaldehyde/agarose gel
and transferred to a nylon filter (Hybond N, Amersham, Arling-
ton Heights, IL, USA) by capillary blotting as described [35]. The
following cDNA probes were [32P]dCTP-labeled by random
primer extension: for PDGF B-chain, linearized plasmid p3-4a, a
clone containing almost the full length of rat PDGF B-chain
cDNA (gift of C. Giachelli, Seattle, WA, USA); for PDGF 13
receptor, a 5.1 kb EcoRi fragment of mouse PDGF f3 receptor
cDNA (gift of D. Bowen-Pope, Seattle, WA, USA) [37]; for
TGF-p1, a 985 bp HindIII/XbaI eDNA fragment from the plasmid
rat TGF-/31 (gift of A. Roberts, National Institutes of Health)
[38]; for laminin B2, a 1.7 kb EcoRIIXbaI fragment of mouse
laminin B2 cDNA from plasmid p1298 [39]; for type I collagen, an
EcoRl fragment of human ai(I) collagen from cDNA clone HF
677 (gift of M. Chu) [40]; for type IV collagen, a 1.8 kb
EcoRI/HindIII fragment of mouse al (IV) collagen cDNA from
plasmid pPE123 (gift of M. Kurkinen) [41]; and for 28S ribosomal
RNA, a 280 bp EcoRI cDNA fragment from bovine 28S RNA
(gift of L. Iruela-Arispe, Univ. of WA, Seattle, WA, USA) [7].
Two to five Northern blots were performed with each probe.
Some membranes were stripped and re-probed. Densitometry
readings from autoradiograms were normalized to 28S ribosomal
RNA, and the ratio of IFN-y to control was reported as "relative
change" [7].
Other measurements
Blood urea nitrogen was measured in serum samples by auto-
analyzer. Urine protein was measured on 24-hour urine specimens
collected in metabolic cages using a sulfosalicylic acid method
with whole serum standards (Lab Trol, Dade Diagnostics,
Aquado, Puerto Rico) as described previously [2].
Statistical analysis
All values shown are mean SD. Statistical significance (de-
fined as P < 0.05) was evaluated using the Student's t-test.
Results
The injection of anti-Thy 1 antibody resulted in the typical
course of mesangial cell loss and matrix disruption (maximal in
the first 24 hours) followed by a phase of mesangial cell prolifer-
ation and matrix expansion [i, 7, 8, 11].
Effect of IFN-y on mesangial cell proliferation, leukocyte
accumulation, and mesangial phenotype change
Cell proliferation was assessed by immunostaining tissue sec-
tions for PCNA, a nuclear accessory protein to DNA polymerase
delta which is expressed from late Gi to M phase of the cell cycle
4b
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Fig. 1. Shown are representative gloineruli with different scores for type IV collagen. The scoring system is detailed in the Methods Section. Glomeruli are
shown with scores of 1 (A), 2 (B), 3 (C), and 4 (D). Scoring is based primarily on distribution rather than intensity (400X, immunoperoxidase).
[42, 43], and which has been previously shown by us to correlate
with cell proliferation in rat kidney tissue as measured by uptake
of 3H-thymidine [44]. Treatment with IFN-y had only a minor
effect on total cell proliferation, as noted by a mild reduction of
PCNA positive cells at day 4 (Table 1).
In contrast, IFN-y treatment dramatically increased the gb-
merular macrophage accumulation by nearly twofold at days 2 and
4 (Table 1). This effect was no longer present four days after the
last IFN-y injection (that is, day 7 after induction of anti-Thy 1
disease) (Table 1).
In previous studies we have documented that 85% of the
proliferating cells in this model are glomerular (primarily mesang-
ial) cells whereas 15% are proliferating macrophages [1, 7, 8, 11].
In order to determine if this were also true in rats treated with
IFN-y, tissue was double immunostained for both PCNA and
monocyte-macrophages (that is, ED-i). In comparison to vehicle-
injected rats with anti-Thy 1 nephritis, IFN-y treated rats with
anti-Thy 1 nephritis had a two- to threefold increase in prolifer-
ating macrophages, which represented 35 to 42% of the total
proliferating cells at days 2 and 4 (Table 1). In contrast, IFN-y
treated rats with anti-Thy 1 disease had a 44% reduction in
proliferating cells that excluded the macrophage marker at days 2
and 4 (Table 1). This strongly suggests that IFN-y reduced
mesangial cell proliferation.
A characteristic of mesangial cells in both experimental and
human mesangial proliferative glomerulonephritis is their up-
regulated (in human) or de novo (in rat) expression of a-smooth
muscle actin [6, 7]. Despite reducing mesangial cell proliferation,
Table 1. Effect of IFN-y on cell proliferation and macrophage
accumulation in glomeruli of rats with mesangial proliferative nephritis
Day2 Day4
Vehicle IFN-y Vehicle IFN-y
Total PCNA + cells 16.5 2.2 14.4 1.5 17.7 2.0 13.4 2.5'
PCNA+, ED-i-- cells 13.7 1.9 8.3 0.9c 16.0 2.0 8.8 2.1c
PCNA+, ED-i+ cells 2.8 0.9 6.1 0.8c 1.7 0.7 4.6 1.3'
Total ED-1+ cells 5.8 0.9 10.4 1.9 3.9 2.1 7.5 2.1
N 5 6
Day 7
Vehicle IFN-y
6 6
Total PCNA+ 4.4 1 3.8 1
Total ED-i+ 5.2 1 5.5 2
N 4 4
Values shown represent the number of positive cells per gbomerular
cross section. For comparison, normal gbomeruli have 0.9 0.2 PCNA-
positive cells and 2.7 0.3 ED-i positive cells per glomerular cross section
[33].
ap < 0.02; bp < 0.001; C < 0.001 comparing vehicle-injected to
IFN-y-injected rats with anti-Thy 1 disease at similar time points
IFN-y treatment did not significantly reduce mesangial a-smooth
muscle actin immunostaining at any time (such as, 2.1 0.6 vs. 2.2
0.6 in IFN-y vs. vehicle-injected rats with anti-Thy 1 nephritis,
day 4, scale 0 to 4+, P = NS).
The increase in glomerular monocyte/macrophages observed in
IFN-treated rats was also parallelled by an increase in cells
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Fig. 2. Light microscopy showing the presence of hydrogen peroxide secreting
cells in the glomerulus of a rat with anti-Thy 1 nephritis that has been treated
with IFN--y (400x).
secreting hydrogen peroxide. In normal rats, hydrogen peroxide-
positive cells are rare (0.4 0.2 cells/glomerular cross section, N
= 4). However, in rats with anti-Thy 1 glomerulonephritis, an
increase in hydrogen peroxide-positive cells was observed, which
was even greater in IFN-y treated rats (0.56 0.32 vs. 1.02 0.22
cells/glomerular cross section in controls vs. IFN-y treated rats
with anti-Thy 1 disease, day 2, N = 5 per group, P < 0.05; Fig. 2).
There was also an increase in the percent of glomeruli in IFN-y
treated rats that had two or more hydrogen peroxide-positive cells
(14 9% vs. 29 11% in controls vs. IFN-y treated rats with
anti-Thy 1 disease, P < 0.05).
IFN-y treatment also increased the number of OX-22 positive
leukocytes (that is, primarily lymphocytes) in glomeruli at day 4
relative to disease controls (1.0 0.4 vs. 0.7 0.2 OX-22+
cells/glomerular cross section, respectively, P < 0.05). However,
no difference was noted at day 7 (data not shown). Neutrophils (as
detected by the monoclonal antibody, RP-3) were scarce in both
vehicle and IFN-y treated rats with anti-Thy 1 disease (averaging
0.1 cell/glomerular cross section).
Effect of IFN-y on glomendar expression of mRNA for PDGF B
chain and TGF-/3
Northern analysis was performed for several growth factors and
matrix components on total glomerular RNA isolated from IFN-y
and vehicle-treated rats with anti-Thy 1 nephritis (Fig. 3). PDGF
B-chain and TGF-f3 mRNA, which are up-regulated in anti-Thy 1
nephritis [35, 45], were further increased 1.6- to 1.8-fold by IFN-y
treatment at day 4 (Fig. 3), In contrast, PDGF 13 receptor mRNA,
which is also up-regulated in anti-Thy 1 nephritis [35], was not
further enhanced by IFN-y treatment (Fig. 3). The increased
expression of PDGF and TGF-f3 mRNA in IFN-y treated rats
with anti-Thy 1 nephritis was no longer observed at day 7 (that is,
4 days after the IFN-y injections had been stopped; data not
shown).
Effect of IFN-y treatment on extracellular matrix expansion in
mesangial proliferative nephritis
Both PAS and silver-stained tissue sections showed comparable
degrees of increased mesangial matrix expansion in IFN-y or
vehicle-injected rats with anti-Thy 1 nephritis at days 4 and 7.
Many glomeruli in both IFN-y and vehicle treated rats with
PGDF receptor
Fig. 3. Effect of IFN--y on growth factor mRNA in anti-Thy 1 nephritis at day
4. Shown are Northern blots of PDGF B chain, PDOF J3 receptor, and
TGF-/3 mRNA and 28S ribosomal RNA in rats with anti-Thy 1 nephritis
that have been treated with vehicle (A) or IFN-y (B). For each blot,
densitometry scores were normalized for 28S ribosomal RNA and the
relative change in densitometry between IFN-y treated rats and disease
controls calculated. The mean densitometry score was 1.8 for PDGF B
chain mRNA, 1.1 for PDGF 13 receptor mRNA, and 1.6 for TGF-13
mRNA.
anti-Thy 1 nephritis showed loss of normal glomerular architec-
ture in areas of mesangial expansion (Fig. 4). There were also no
differences between groups when tissue was immunostained for
type I collagen, type IV collagen, or laminin (Table 2). In contrast,
type IV collagen and laminin B2 mRNA were increased by 1.4-
and 1.7-fold, respectively, in glomerular RNA from rats with
nephritis that had received IFN-y when compared to vehicle-
injected controls (Fig. 5).
Effect of IFN-y treatment on renal function and proteinuria in
mesangial proliferative nephritis
Blood urea nitrogen concentrations were marginally higher in
IFN-y treated rats with nephritis, although this was clinically
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Fig. 4. Light microscopy of glomendi from rats with mesangial proliferative
nephritis at day 7 that either received vehicle or IFN- An increase in
glonierular cellularity with distortion of glomerular architecture is present
in both vehicle (A) and IFN-y treated rats (B) with mesangial proliferative
nephritis (Jones methenamine silver stain, 400X).
Day4 Day7
IFN-y Vehicle IFN-y Vehicle
Type IV collagen 2.8 0.3 2.9 0.3 2.2 0.3 2.5 0.4
Type I collagen 1.4 0.3 1.6 0.7 1.4 0.2 1.3 0.6
Laminin 2.7 0.2 2.7 0.4 2.8 0.3 2.6 0.4
insignificant (23 2 vs. 20 1 mgldl in IFN-y vs. vehicle-injected
rats with nephritis, day 4, P < 0.02). Proteinuria was no different
in IFN-y treated versus control rats with nephritis (33 20 vs. 25
9 mg/24 hrs in IFN-y vs. vehicle, days 3 to 4, P NS).
Effect of IFN-y on normal rats
Limited studies were also performed in which normal rats
either received IFN-y or saline vehicle. IFN-y did not induce a
macrophage influx or affect cell proliferation (PCNA). Normal
rats treated with IFN-y also had no difference in type IV collagen
and laminin by immunostaining compared to normal rats.
Fig. 5. Effect of IFN--y on extracellular matrix mRNA in anti-Thy 1 nephritis
at day 4. Shown are Northern blots for types ol (IV) and al(I) collagen
and laminin B2 inRNA and 28S ribosomal RNA in rats with anti-Thy 1
nephritis that have been treated with vehicle (A) or IFN-y (B). For each
blot, densitometry scores were normalized for 28S ribosomal RNA and the
relative change in densitometry between IFN-y treated rats and disease
controls calculated. The mean densitometry score was 1.4 for type IV
collagen [al (IV)] mRNA, 1.2 for type I collagen [al (I)] mRNA, and 1.7
for laminin B2 mRNA.
Discussion
IFN-y is a multipotent cytokine produced by activated T cells
and NK cells that has anti-proliferative, immunomodulatory, and
anti-viral effects [46]. We administered recombinant rat IFN-y
(10 U/kg) to rats with mesangial proliferative nephritis induced
by anti-Thy 1 antibody in order to determine if it would have a
beneficial effect on the disease by reducing mesangial cell prolif-
eration, phenotype change, and matrix expansion. The IFN-y
injections were started one day after the disease induction so as to
eliminate concerns over whether or not the IFN-y would affect the
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Type IV collagen
Type I collagen
Laminin
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Table 2. Effect of IFN-y on mesangial matrix expansion of types I and
IV collagen and laminin in mesangial proliferative nephritis induced
with anti-Thy 1 antibody
Values shown represent a mean so of a semi-quantitative grade (0 to
4+) for mesangial matrix expansion as determined by immunostaining
with specific antibodies [8]. Comparable values in normal rats (of same age
and weight) are, for type IV collagen, 2.2 0.1; for type I collagen, 0.1
0.03; and for laminin 2.0 0.1.
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initial binding of the anti-Thy 1 antibody (which is maximal at 1 hr
[47]) or with the acute complement-mediated mesangiolysis.
Initiation of IFN-y injections after disease induction is also of
more relevance to the question of whether or not IFN-'y may be
clinically useful in the treatment of glomerular disease.
Treatment with IFN-y only mildly reduced total glomerular cell
proliferation (that is, PCNA-positive cells) at day 4. However,
these proliferating cells could be separated by double immunos-
taming into those cells that were proliferating macrophages (that
is, PCNA +, ED-i +) and proliferating cells that excluded the
macrophage marker (that is, PCNA +, ED-i —) which are likely
glomerular (and primarily mesangial) cells. Using this technique,
one could demonstrate a significant increase in proliferating
macrophages in glomeruli with a concomitant reduction (44%) in
other proliferating cells at both days 2 and 4. That this reduction
in proliferating cells represented primarily mesangial cells is
supported indirectly by the minimal numbers of other leukocytes
in these glomeruli, and by our previous studies which have
demonstrated that the majority of the PCNA-positive cells in this
model express Thy 1 (a marker for mesangial cells) and a-smooth
muscle actin (a marker for activated mesangial cells) [1, 7, 8, 11,
35]. However, a contribution by other endogenous glomerular
cells (that is, endothelial cells) cannot be excluded.
The mechanism for the anti-proliferative effect of interferon on
the mesangial cell in this model may be direct, as it is known that
IFN-y may inhibit the proliferation of a variety of cell types in
culture, including mesangial cells, smooth muscle cells, and fibro-
blasts [16—211. Indeed, IFN-y inhibits the proliferative response
of rat mesangial cells to PDGF [17, and RJ Johnson et al,
unpublished data], which has been shown to be an important
mediator of cell proliferation in this model [12, 35]. Studies in
human fibroblasts suggest that the inhibitory effects of IFN-y on
PDGF-mediated cell proliferation occur distal to the PDGF
receptor [21]. This could potentially explain why IFN-y inhibited
the glomerular cell proliferation in this model despite inducing an
increase in PDGF B-chain mRNA expression.
The inhibitory effects of IFN-y on glomerular cell proliferation
may also be indirect. For example, TGF-3 mRNA expression was
up-regulated in glomeruli of rats with IFN-y treatment. TGF-/3
inhibits mesangial cell proliferation under most conditions in vitro
[48, 49] despite the fact that TGF-13 also induces PDGF mRNA
expression in these cells [48]. IFN-y also activates macrophages to
produce nitric oxide (endothelium-derived relaxing factor) [50],
which is a potent inhibitor of mesangial cell proliferation to a
variety of mitogens, including PDGF [reviewed in 51]. Other
inhibitory factors may also be induced. For example, we have
evidence that SPARC/osteonectin, which can inhibit mesangial
cell proliferation in culture, is induced by IFN-y treatment in this
model (unpublished observations).
Despite the inhibition of mesangial cell proliferation, there was
no significant reduction of a-smooth muscle actin expression. We
had originally reported that a-smooth muscle actin was a marker
for proliferating mesangial cells in glomerulonephritis [7]. How-
ever, we have subsequently been able to show that the a-smooth
muscle actin expression and mesangial cell proliferation can be
dissociated; for example, with angiotensin II infusion (in which
a-actin is expressed despite minimal mesangial cell proliferation
[44]) or with PDGF infusion (in which mesangial cell proliferation
occurs without a-smooth muscle actin expression [52]). Whereas
we had expected that IFN-y would reduce both the mesangial cell
proliferation and a-actin expression, it is possible that IFN-y may
have inhibited proliferation, but due to expression of other
factors, such as TGF-p, that the phenotype was not altered.
Recently it has been reported that TGF-3 induces a-smooth
muscle actin in granulation tissue myofibroblasts and in cultured
fibroblasts [53].
The second major finding was that treatment of mesangial
proliferative nephritis with IFN-y resulted in a near doubling of
the monocyte/macrophage accumulation in glomeruli. Many of
these monocyte-macrophages were expressing the proliferation-
associated marker, PCNA, suggesting that they were proliferating
in the glomeruli or had arrived in the glomeruli shortly after
proliferating in the marrow or lymph nodes. An increase in cells
expressing hydrogen peroxide was also observed. These oxidant-
producing cells were most likely monocytes. This is based on the
observation that only neutrophils and monocytes contain the
endogenous peroxidase (that is, myeloperoxidase) necessary for
the assay to detect hydrogen peroxide and neutrophils were not
present in these lesions. It is also known that IFN-y significantly
increases the cytotoxicity and oxidant production by monocyte/
macrophages in response to stimuli [54].
It is possible that the increased localization of activated mac-
rophages in this model counteracted the effects of IFN-y on
reducing the mesangial cell proliferation. Indeed, the original
hypothesis, that a reduction in mesangial cell proliferation would
translate into a reduction in extracellular matrix, was not ob-
served, as immunostaining for matrix proteins was not different
between groups, and matrix mRNA levels were in fact increased
in IFN-y treated animals. We [55] and others [56, 571 have
previously shown a tight correlation between macrophage influx,
matrix expansion, and glomerular sclerosis in other experimental
models of nephritis. If macrophages are responsible for the
increase in extracellular matrix, the mechanism could relate to
expression of TGF-13 by the macrophage itself, or to macrophage
stimulation of other (such as, mesangial) cells to express TGF-13.
TGF-f3 stimulates the production of extracellular matrix by a
variety of cells, including mesangial cells [49, 581, and has been
shown to be a mediator of matrix expansion in the anti-Thy 1
model [59].
This study also provides insights into potential discrepancies
between in vitro and in vivo data in relation to IFN-y. The findings
that IFN-y inhibits cell proliferation [16—21, 23] and collagen
production [25—28] of a variety of cell types in culture suggest that
it may be useful in the treatment of fibroproliferative diseases
such as interstitial pneumonitis, fibrosing hepatic diseases and
glomerulonephritis. However, lupus mice (the NZB/NZW F1
hybrid) treated with IFN-y have increased proteinuria, onset of
glomerulonephritis, and mortality [60, 61]. Increased glomerular
cellularity and sclerosis was also observed with IFN-y treatment in
a murine model of IgA nephropathy [62]. However, the effects of
IFN-y on disease processes may also vary depending on the
specific disease process or the tissue involved.
In conclusion, IFN-y has multiple effects in experimental
glomerulonephritis. While it has anti-proliferative effects on gb-
merular cells, it also increases gbomerular macrophage localiza-
tion and activation. In addition to characterizing the effects of
IFN-y in nephritis, this study provides some interesting insights
into glomerular biology. First, it provides evidence that significant
numbers of macrophages in glomeruli may express proliferation
markers (which is of relevance in all studies in which glomerular
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cell proliferation is examined). Second, it demonstrates that cell
proliferation and matrix expansion are not necessarily concordant,
but can be partially dissociated. And finally, it provides further,
albeit indirect, evidence that matrix expansion may be linked to
macrophages and TGF-j3 expression.
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proliferating cell nuclear antigen; PDGF, platelet-derived growth factor;
TGF-13, transforming growth factor f3.
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